Full length article

Perception of whole-body motion during balance perturbations is impaired in Parkinson's disease and is associated with balance impairment

Sistania M. Bonga, J. Lucas McKay, Stewart A. Factor, Lena H. Ting

A Wallce H. Coulter Department of Biomedical Engineering, Emory University and Georgia Tech, Atlanta, Georgia, USA
b Jean & Paul Amos PD & Movement Disorders Program, Department of Neurology, Emory University School of Medicine, Atlanta, Georgia, USA
c Division of Physical Therapy, Department of Rehabilitation Medicine, Emory University School of Medicine, Atlanta, Georgia, USA

ARTICLE INFO

Keywords:
Parkinson’s disease
Perception
Posture
Balance

ABSTRACT

Background: In addition to motor deficits, Parkinson's disease (PD) may cause perceptual impairments. The role of perceptual impairments in sensorimotor function is unclear, and has typically been studied in single-joint motions.

Research question: We hypothesized that perception of whole-body motion is impaired in PD and contributes to balance impairments. We tested (1) whether directional acuity to whole body perturbations during standing was worse in people with PD compared to neurotypical older adults (NOA), and (2) whether balance ability, as assessed by the MiniBESTest, was associated with poor directional acuity in either group.

Methods: Participants were exposed to pairs of support-surface translation perturbations in a two-alternative forced choice testing paradigm developed previously in a young healthy population. The first perturbation of each pair that was to be judged by participants was directly backward, and the second perturbation deviated from the left or right from the backward direction by 1°–44°. Participants reported whether the perturbations in each pair were in the “same” or “different” direction. Judgements from 24 to 67 perturbation pairs were used to calculate directional acuity thresholds corresponding to “just-noticeable differences” in perturbation direction. Linear mixed models determined associations between directional thresholds and clinical variables including MDS-UPDRS-III score, age, and MiniBESTest score.

Results: 20 PD (64 ± 7 y, 12 male, ≥12 h since last intake of antiparkinsonian medications) and 12 NOA (64 ± 8, 6 male) were assessed. Directional thresholds were higher (worse) among PD participants (17.6 ± 5.9° vs. 12.8 ± 3.3°, P < 0.01). Linear mixed models further showed that higher thresholds were associated with MDS-UPDRS-III score (P < 0.01), and were associated with poorer balance ability among PD participants (P < 0.01), but not among NOA participants (P = 0.40).

Significance: Perception of whole-body motion is impaired in PD and may contribute to impaired balance and falls.

1. Introduction

Deficits in somatosensory perception have been identified in Parkinson’s disease (PD) [1–8], but their relationship to impaired balance is unclear. PD causes profound balance problems and falls [9], resulting in significant morbidity, mortality, and reduced quality of life [10–12]. Because standing balance requires complex sensorimotor integration [13–15], impairments in the sensing body motion may contribute to balance impairments. In laboratory studies using perturbation testing, balance-correcting muscle responses evoked by perturbations are less directionally-specific in people with PD than in matched individuals [16,17], with broader directional tuning to perturbation direction that could be explained by an impairment in the ability to accurately sense the direction of body motion. Our goal was to explicitly test whether perception of whole-body motion direction is impaired in individuals with PD, and if so, to test whether this impairment is related to impaired balance.

Somatosensory perceptual deficits in PD have been typically investigated in single-joint tasks [3,7,18–20] usually of isolated limbs [21–23]. Results demonstrate impaired perception of the position of
Adaptively online threshold $\theta$ was altered of +3° or were in the "Same" or "Different" direction. Thus, it was hypothesized that some aspects of whole body may be impaired in PD [21,24,27]; however, whether these impairments impact perception of whole-body motion direction during standing remains unknown.

We developed a balance testing paradigm to quantify the perception of whole-body motion direction during backward perturbations to standing balance in young healthy subjects using a "Parameter Estimation by Sequential Testing" (PEST) algorithm [28,29]. We quantified just-noticeable differences in the judgement of lateral deviations of backward support-surface translations during standing using a two-alternative forced choice paradigm, and identified a directional threshold of about 10° [29]. We demonstrated that this algorithm required far fewer trials than conventional psychophysical methods, making testing feasible in clinical populations.

In this study, we quantified left-right angle deviation directional acuity of whole-body motion arising from backward perturbations to standing balance in individuals with PD and matched neurotypical older adults. We hypothesized that (1) whole-body motion directional acuity would be impaired in people with PD, and (2) impaired whole-body motion directional acuity would be associated with impaired balance, as assessed with a behavioral clinical balance scale in common clinical use in PD, the MiniBESTest [30,31].

2. Methods

2.1. Participants and setting

We performed a cross-sectional study of whole-body motion perception in community-dwelling individuals with PD and age- and sex-similar neurotypical older adults (NOA). Participants were recruited from the Jean & Paul Amos Parkinson’s Disease and Movement Disorders Clinic at Emory University School of Medicine, community outreach events, senior centers and similar venues. PD subjects were recruited from the study population of an observational 1-year fall risk study. NOA participants were recruited for a one-time visit. Sample size for both groups was selected to meet or exceed general guidelines of N = 12 recommended for pilot studies [32].

All participants were age ≥56 years without a history of musculoskeletal and/or neurological disorders, other than PD, sensory deficits, or dizziness. Participants with PD were diagnosed with idiopathic PD and cleared for participation in the study by their neurologist. All participants provided informed consent prior to participation according to a protocol approved by Institutional Review Board of Emory University.

2.2. Study visit

Informed consent and all testing procedures were performed during a single ≈3 h study visit. PD participants were assessed in the practically defined OFF state [33], which is ≥12 h after last intake of anti-parkinsonian medications. Demographic and clinical information were collected using standardized instruments (Supplementary Materials S1).

2.3. Whole-body motion perception testing

Participants stood barefoot on a custom perturbation platform that translated in the horizontal plane, wore a harness attached to the ceiling, and were attended by staff [17,34]. Stance width between the feet was standardized to inter-anterior superior iliac spine (ASIS) distance. Participants were blindfolded and wore headphones that played white noise to eliminate visual and auditory feedback. Participants were instrumented with electromyography electrodes on the legs and reflective motion capture markers [17,34].

Directional acuity threshold of a whole-body motion was defined as the smallest detectable difference in lateral deviations between pairs of sequential perturbations during standing (Fig. 1). Each trial consisted of a pair of two ramp-and-hold translations of the support surface (7.5 cm displacement, 15 cm/s peak velocity, 0.1 m/s² peak acceleration) [17,34]. The first perturbation of each pair was delivered in the backward direction, causing the body center of mass to be displaced anteriorly with respect to the ankles. The second perturbation of each pair was delivered 0.5 s after the first perturbation ended, and deviated in a pseudo-random fashion either to the left or to the right from the backward direction, and by an amount $\Delta\theta$ determined adaptively online using the PEST [29] with an initial $\Delta\theta$ of +3° or −3°, an initial step size
Table 1
Demographic and clinical characteristics of study participants.

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>PD N = 20</th>
<th>NOA N = 12</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, y</td>
<td>64.4 ± 6.7</td>
<td>64.2 ± 7.9</td>
<td>0.99</td>
</tr>
<tr>
<td>Sex</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Female</td>
<td>8 (40)</td>
<td>6 (50)</td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>12 (60)</td>
<td>6 (50)</td>
<td></td>
</tr>
<tr>
<td>Height, cm</td>
<td>172 ± 11.3</td>
<td>173 ± 10.2</td>
<td>0.84</td>
</tr>
<tr>
<td>Weight, kg</td>
<td>80.1 ± 9.5</td>
<td>84.0 ± 14.6</td>
<td>0.37</td>
</tr>
<tr>
<td>MoCA, /30</td>
<td>27.3 ± 2.2</td>
<td>27.4 ± 2.5</td>
<td>0.88</td>
</tr>
<tr>
<td>Education, y</td>
<td>16.3 ± 1.8</td>
<td>15.7 ± 1.7</td>
<td>0.41</td>
</tr>
<tr>
<td>Disease duration, y</td>
<td>8.0 ± 5.2</td>
<td></td>
<td></td>
</tr>
<tr>
<td>MDS UPDRS-I/52</td>
<td>11.1 ± 5.4</td>
<td></td>
<td></td>
</tr>
<tr>
<td>MDS UPDRS-II/52</td>
<td>13.3 ± 5.7</td>
<td></td>
<td></td>
</tr>
<tr>
<td>MDS UPDRS-III/108</td>
<td>27.9 ± 9.8</td>
<td></td>
<td></td>
</tr>
<tr>
<td>MDS UPDRS-IV/24</td>
<td>4.8 ± 2.4</td>
<td></td>
<td></td>
</tr>
<tr>
<td>FOG-Q-24</td>
<td>4.5 ± 3.9</td>
<td></td>
<td></td>
</tr>
<tr>
<td>LEDD, mg²</td>
<td>806 ± 471</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mini-BESTest./28</td>
<td>22.2 ± 3.3</td>
<td>25.7 ± 1.7</td>
<td>&lt; 0.01</td>
</tr>
<tr>
<td>Falls, 6 months (N, %)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0</td>
<td>8 (40)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1</td>
<td>6 (30)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>3+</td>
<td>6 (30)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Freezing of Gait (N, %)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Freezer</td>
<td>8 (40)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Non-freezer</td>
<td>12 (60)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hoehn &amp; Yahr Stage, (N, %)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1</td>
<td>0 (0)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2</td>
<td>15 (75)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>3</td>
<td>5 (25)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Abbreviations: PD, Parkinson’s disease; NOA, neurotypical older adults; MoCA, Montreal Cognitive Assessment [36]; MDS-UPDRS, Unified Parkinson’s Disease Rating Scale, Movement Disorders Society Revision [51]; FOG-Q, Freezing of Gait Questionnaire [52]; LEDD, Levodopa Equivalent Daily Dose [53].

2.4. Data analysis

Threshold values Δθ\_Threshold were obtained from the left and right side of each participant and were reclassified in ascending order of magnitude as minimum and maximum. In cases where convergence was not reached, threshold values were estimated using a psychometric curve fit to the PEST response data (Supplementary Materials S1).

2.5. Statistical analysis

Differences in demographic and clinical features between PD and NOA groups were assessed with chi-squared tests and independent samples t-tests as appropriate. Additional t-tests evaluated perceptual asymmetry between maximum and minimum thresholds in each participant and across groups. Differences between maximum and minimum threshold values were log-transformed prior to analysis in order to meet criteria for approximate normality as determined by the Kolmogorov-Smirnov test.

Overall differences between PD and NOA in identified threshold values were assessed using independent samples t-tests. Multivariate linear mixed models were used to further examine the contributions of age and parkinsonian severity to the perception of whole-body motion. We fit the following model to each of the maximum and minimum thresholds Δθ\_Threshold:

\[ \Delta \theta_{\text{Threshold}} = \beta_0 + \beta_1 \cdot \text{Age} + \beta_2 \cdot \text{PD} + \beta_3 \cdot \text{UPDRS} + \varepsilon \]

where Δθ\_Threshold corresponds to the identified threshold value from either side of the body, Age corresponds to age in years, PD is a dichotomous variable coding the presence of PD, and UPDRS specifically represents MDS-UPDRS-III (motor examination) score. MDS-UPDRS-III scores were centered about zero prior to entry in linear mixed models.

To test hypothesis 1: whether whole-body motion directional acuity is impaired in people with PD, the null hypothesis β2 = 0 was evaluated with an F-test.

To test hypothesis 2: whether impaired perception of whole-body motion direction is associated with impaired balance deficits, we constructed linear mixed models that regressed observed MiniBESTest scores onto observed threshold values, with interaction terms that allowed for different regression coefficients among the NOA and PD groups. Separate models were constructed for each of the maximum and minimum thresholds, structured as follows:

\[ \text{MiniBESTest} = \beta_1 + \beta_2 \cdot \Delta \theta_{\text{Threshold}} + \beta_3 \cdot \text{PD} + \beta_4 \cdot \text{PD} \cdot \Delta \theta_{\text{Threshold}} + \varepsilon \]

To test whether impaired perception of whole-body motion direction was associated with balance deficits, we evaluated the following null hypothesis using F-tests. First, to test whether impaired perception was associated with balance deficits among NOA, the reference group, we evaluated β3 = 0. Second, to test whether impaired perception was associated with balance deficits among PD, we evaluated β4 = 0. Finally, to test whether associations were significantly different among the NOA and PD groups, we evaluated β3 = 0.

2.6. Additional analyses

Additional analyses considered: (1) comparison to young healthy adults [29], (2) Clinical and demographic features associated with incomplete convergence or failure to complete testing; (3) motor symptom asymmetry [35] (Supplementary Materials S1).

3. Results

3.1. Demographic and clinical characteristics

Demographic and clinical characteristics of PD (N = 20, 12 male, age 64 ± 7 y, disease duration 8 ± 5y) and NOA groups (N = 12, 6 male, age 64 ± 78 y) are summarized in Table 1. No significant group differences were identified between PD and NOA in sex, age, height, weight, or MoCA [36]. Age ranges were 56–80 (PD) and 56–81 (NOA). PD patients had significantly poorer performance on MiniBESTest (3.5 points, p = 0.0018). Average MoCA scores were indicative of normal cognition (> 27) in both groups. 8/20 (40%) PD participants were classified as “freezers” [37]. 19/20 PD participants were prescribed antiparkinsonian medications at the time of enrollment; 1 participant had not yet begun pharmacotherapy.

In addition to these participants, testing was attempted but not completed in N = 14 additional participants (N = 10 PD, N = 4 NOA). Neither the frequency of nor the reasons for early termination varied across groups (P = 0.50 and P = 0.28, respectively; reasons summarized in Supplementary Materials S1). Inability to complete testing was
3.2. Whole-body directional acuity is impaired in PD

Independent samples t-tests showed that directional acuity thresholds were significantly larger in PD vs. NOA (maximum $\Delta \theta_{\text{threshold}}$: $17.6 \pm 5.9^\circ$ vs. $12.8 \pm 3.3^\circ$, $p = 0.016$; minimum $\Delta \theta_{\text{threshold}}$: $13.5 \pm 4.0^\circ$ vs. $9.67 \pm 2.9^\circ$, $p = 0.008$; Fig. 2A,B). Differences between maximum and minimum $\Delta \theta_{\text{threshold}}$ were statistically-significant for both groups ($p < 0.001$). No group differences in this perceptual asymmetry were identified ($p = 0.66$).

Linear mixed models showed that the presence of PD, and PD severity as measured by MDS-UPDRS-III, were both significantly associated with impaired perception of whole-body motion (maximum $\Delta \theta_{\text{threshold}}$: PD presence, $p < 0.001$, PD severity, $p < 0.01$; minimum $\Delta \theta_{\text{threshold}}$: PD presence, $p < 0.01$, PD severity, $p < 0.01$). No significant effects of age were identified (maximum $\Delta \theta_{\text{threshold}}$: $p = 0.32$, minimum $\Delta \theta_{\text{threshold}}$: $p = 0.82$) (Table 2).

In ten participants who completed the planned testing protocol (N = 7, PD; N = 3, NOA), the algorithm failed to converge on one side during the allotted time. These threshold values were estimated using a psychometric curve fit (Table S1). The prevalence of convergence failure did not vary significantly across groups (35%, PD; 25%, NOA; $p = 0.71$). No statistically-significant associations were identified between convergence failure and any clinical or demographic variables examined. The strongest potential association was with impaired MiniBESTest performance ($p = 0.22$).

3.3. Worse balance is associated with impaired directional acuity among PD but not NOA participants

Linear mixed models examining associations between MiniBESTest score and directional acuity identified statistically-significant group x threshold interaction terms for both maximum ($p = 0.017$) and minimum ($p = 0.007$) $\Delta \theta_{\text{threshold}}$ (Fig. 3A,B). Among PD participants, associations between MiniBESTest score and directional threshold were $-0.40$ points/$^\circ$ ($p < 0.001$) and $-0.53$ points/$^\circ$ ($p = 0.002$), for maximum and minimum thresholds, respectively (Table S2). No statistically-significant associations between directional perception and MiniBESTest score were identified among NOA ($p > 0.43$).

3.4. Impaired directional acuity in people with PD is associated with symptom severity

Additional linear mixed models were used to more precisely determine associations between whole-body motion perception and PD severity, as measured either by MDS-UPDRS III score or disease duration. Among PD participants, impaired perception of whole-body motion was associated with more severe MDS UPDRS III scores (maximum $\Delta \theta_{\text{threshold}}$: $p = 0.002$; minimum $\Delta \theta_{\text{threshold}}$: $p = 0.063$; Fig. 4A). Positive, but statistically-insignificant associations were observed between threshold values and disease duration (maximum $\Delta \theta_{\text{threshold}}$: $p = 0.271$; minimum $\Delta \theta_{\text{threshold}}$: $p = 0.770$; Fig. 4B). No significant differences were identified between thresholds on the more or less affected sides ($p = 0.74$).

4. Discussion

Here we identified a new functional perceptual deficit that may lead to falls in PD. To our knowledge, this is the first study investigating whole-body directional perception during standing in people with PD. Consistent with prior work demonstrating altered somatosensation, nociception, thermal sensation, and proprioception in PD [1,2,38], we show that directional acuity to whole-body motion imposed by support surface translations is also impaired. This perceptual deficit is significantly correlated with overall parkinsonian symptom severity, as determined by OFF medication MDS-UPDRS-III score, providing evidence that it may be associated with dopamine loss. This perceptual deficit is also significantly correlated with impaired balance among participants with PD, but not among NOA, supporting the hypothesis that it could represent an underlying cause of impaired balance in this population.

Taken together with data from young healthy individuals, these data show that directional perception of whole-body motion is affected by PD, but probably does not appreciably decline over healthy aging. We found no effect of age on directional perception in our current sample, which was limited to ages 56–82. We also found no significant

---

**Table 2**

Associations between whole-body motion perception, PD, and age determined by linear mixed models.

<table>
<thead>
<tr>
<th>Predictor</th>
<th>Beta coefficient</th>
<th>95% CI</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Maximum threshold - Age (/y)</td>
<td>−0.11</td>
<td>−0.34, +0.11</td>
<td>0.315</td>
</tr>
<tr>
<td></td>
<td>PD (°)</td>
<td>+4.81</td>
<td>+1.71, +7.91</td>
</tr>
<tr>
<td></td>
<td>MDS-UPDRS-III (/point)</td>
<td>+0.43</td>
<td>+0.22, +0.63</td>
</tr>
<tr>
<td>Minimum Threshold - Age (/y)</td>
<td>−0.02</td>
<td>−0.20, +0.17</td>
<td>0.822</td>
</tr>
<tr>
<td></td>
<td>PD (°)</td>
<td>+3.78</td>
<td>+1.21, +6.36</td>
</tr>
<tr>
<td></td>
<td>MDS-UPDRS-III (/point)</td>
<td>+0.21</td>
<td>+0.03, +0.39</td>
</tr>
</tbody>
</table>

* $P < 0.05$.
** $P < 0.01$, significant effect of predictor variable on threshold value, linear mixed models.
differences between the current healthy sample and existing data of a young healthy sample (Supplementary Materials S1). However, we did find that individuals of very advanced age were more likely to be unable to tolerate the testing protocol, whether or not they had Parkinson’s disease. It is therefore possible that directional perception could decline rapidly at very advanced age, interfering with the testing protocol. However, the reasons that individuals of advanced age were unable to complete the protocol were not necessarily related to poor proprioception.

We were somewhat surprised to find no difference in perceptual acuity between the more- and less-affected side of participants with PD. Previously, grating discrimination threshold has been shown to be worse on the more affected side of people with PD [39]. The absence of a strong lateralization effect in this study could reflect the fact that most patients were ≥ Hoehn & Yahr stage 2, with evident bilateral symptoms [40,41]. As somatosensory abnormalities can occur early in disease progression [38], it is possible that directionality deficits could be more lateralized in earlier PD patients with more lateralized symptoms. It is also possible that this deficit may relate to axial symptoms, rather than to lateralized limb features, particularly given that directional acuity likely depends on sensory information from both sides of the body, including vestibular information [27,42], and cutaneous information on the foot soles [45]. Another possibility is that PD patients may exhibit impaired directional acuity on both sides of the body that is independent of the lateralization of motor symptoms. Wright et al. [24] found that trunk rotation discrimination was more impaired in patients with left side symptom onset than with right side symptom onset, but that the discrimination impairment itself was common to both sides of the body; a similar result was found in pointing tasks [21].

Our results suggest that estimates of whole-body directional acuity may be an important and specific contributor to falls in PD. Associations between directional acuity and MiniBESTest scores were seen only in PD and not NOA. We found no statistically-significant associations between impaired directional acuity and fall history, which was available in a subset of participants (N = 20). However, maximum Δθ_threshold had a ≥ 30% stronger relationship to history of falls than the MiniBESTest [46]. Further, participants unable to complete the testing also had significantly reduced balance ability (p < 0.01). Due to sample size limitations, we did not include additional variables (like age or total MDS-UPDRS III score) in correlational analyses. As there was no consistent association between age and direction acuity among NOA participants, it is unlikely that the association between directional acuity and MiniBESTest score in PD is due to common underlying causal effect of age on both variables. However, it is possible that a different common underlying cause (like a particular parkinsonian symptom) could affect both variables.

Our results are consistent with a growing body of evidence showing a variety of sensory deficits in PD that may underlie motor impairments. Studies of somatosensory deficits in PD have primarily examined isolated limbs or single joint tasks [2–8,21,24]. We eliminated visual and auditory inputs, requiring participants to judge whole-body motion direction based only on somatosensory and vestibular inputs [47,48]. The poor directional acuity in PD is consistent with less directionally-specific activation of automatic, brainstem-mediated balance-correcting muscle activity in PD [16,17]. Additionally, reduced perceptual discrimination of whole body motion direction would also impair the efficacy of attentional mechanisms used to compensate for poor automatic balance control [49]. Similarly, deficits in body axial rotation perception during standing [24], and impairments in perceiving leg movement during walking [26] likely contribute to functional sensorimotor deficits.

This study has several important limitations. First, balance ability...
was assessed only once with a behavioral scale. We did not examine variables recorded during perceptual judgements, limiting the ability to relate impaired perception of body motion more precisely to balance deficits. Second, due to sample size limitations, we could not investigate whether many clinical variables – including parkinsonian signs like rigidity and postural instability – were associated with impaired perception of body motion. Third, although no neuropathic signs or diabetic comorbidities were reported in clinic records for these patients, we did not confirm normal proprioception (e.g., vibration testing) during testing. Therefore, latent neuropathy or another comorbidity could contribute to impaired perception of body motion, and the relationship to individual limb proprioception remains unknown. Finally, a substantial proportion of subjects (26%) could not tolerate the testing. These subjects were older, and may have been frazzier overall; therefore, the extent to which these results generalize to older cohorts (> 81 years) is unknown.

Based on the strong association of whole-body perceptual deficits with MDS-UPDRS III score, we speculate that directional acuity would improve with effective symptomatic pharmacotherapy. In this study, all testing was performed ≥ 12 h after intake of dopaminergic medications. The perceptual deficit we identified here is strongly related to overall parkinsonian symptom severity, which generally respond well to acute dopamine challenge [50]. Several groups have also shown that impaired acuity to tackle stimuli improves with dopaminergic therapy [38]. Improving perceptual deficits that may cause falls and other motor deficit may be an additional benefit of careful management of “off”-times of dopaminergic fluctuations. Further PD-specific sensory deficits may contribute to the differences in parkinsonian fall circumstances compared to the general geriatric population [9].

Conflict of interest

Funding sources

This study was supported in part by National Institutes of Health grants 2R01HD046922, R01 HD090642, K25HD086276, and the Sartain Lanier Family Foundation. The sponsors had no role in the conduct or publication of the work.

Financial disclosures for the previous 12 months

Ms. Bong has nothing to disclose.
Dr. McKay has received research funding or support from the National Institutes of Health.
Dr. Factor has received research funding or support from the National Institutes of Health, the Michael J. Fox Foundation, Ipsen, Medtronic, Boston Scientific, Teva, US World Meds, Sunovion Therapeutics, Vaccinex, Voyager, Jazz Pharmaceuticals, CHDI Foundation. Dr. Factor has received honoraria from Lundbeck, Teva, Sunovion, Biogen, Acadia, Neuroderm. Dr. Factor has received royalties from Blackwell Futura, Demos, Springer and UpToDate.
Dr. Ting has received research funding or support from the National Institutes of Health and the National Science Foundation.

CRediT authorship contribution statement

Sistania M. Bong: Data curation, Formal analysis, Investigation, Software, Validation, Visualization, Writing - original draft, Writing - review & editing, Supervision. J. Lucas McKay: Data curation, Formal analysis, Funding acquisition, Investigation, Methodology, Software, Validation, Visualization, Writing - original draft, Writing - review & editing, Resources. Stewart A. Factor: Data curation, Funding acquisition, Investigation, Methodology, Project administration, Resources, Software, Supervision, Validation, Visualization, Writing - original draft, Writing - review & editing.

Acknowledgements

This study was supported in part by National Institutes of Health grants 2R01HD046922, R01 HD090642, K25HD086276, and the Sartain Lanier Family Foundation. The funders had no role in the conduct or publication of the study.

Appendix A. Supplementary data

Supplementary material related to this article can be found, in the online version, at doi:https://doi.org/10.1016/j.gaitpost.2019.10.029.

References


